Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351123 | 0.91 | AKT1 (0.39) | AKT1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1352087 | 0.90 | AKT1 (0.38) | AKT1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1350490 | 0.88 | AKT1 (0.41) | AKT1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1351431 | 0.87 | GPBAR1 (0.42) | AKT1ALDH1A1 | |
| SCHEMBL1350017 | 0.86 | AKT1 (0.38) | AKT1DHODH | |
| SCHEMBL1351444 | 0.86 | AKT1 (0.35) | AKT1MEN1KMT2ALTB4RDHODH | |
| SCHEMBL1352166 | 0.85 | ADK (0.42) | AKT1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1349890 | 0.85 | DHODH (0.41) | AKT1MEN1KMT2ALTB4RDHODH | |
| SCHEMBL1352644 | 0.85 | AKT1 (0.39) | AKT1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1351888 | 0.84 | AKT1 (0.40) | AKT1MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885MEN1 1098/4885KMT2A 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.